JP2011529942A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529942A5
JP2011529942A5 JP2011521561A JP2011521561A JP2011529942A5 JP 2011529942 A5 JP2011529942 A5 JP 2011529942A5 JP 2011521561 A JP2011521561 A JP 2011521561A JP 2011521561 A JP2011521561 A JP 2011521561A JP 2011529942 A5 JP2011529942 A5 JP 2011529942A5
Authority
JP
Japan
Prior art keywords
crystalline form
compound
formula
methylbenzenesulfonate
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011521561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529942A (ja
Filing date
Publication date
Priority claimed from GBGB0814340.6A external-priority patent/GB0814340D0/en
Application filed filed Critical
Publication of JP2011529942A publication Critical patent/JP2011529942A/ja
Publication of JP2011529942A5 publication Critical patent/JP2011529942A5/ja
Withdrawn legal-status Critical Current

Links

JP2011521561A 2008-08-05 2009-08-04 ピリジン誘導体の結晶体 Withdrawn JP2011529942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0814340.6 2008-08-05
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (2)

Publication Number Publication Date
JP2011529942A JP2011529942A (ja) 2011-12-15
JP2011529942A5 true JP2011529942A5 (cg-RX-API-DMAC7.html) 2012-09-27

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521561A Withdrawn JP2011529942A (ja) 2008-08-05 2009-08-04 ピリジン誘導体の結晶体

Country Status (14)

Country Link
US (1) US8093242B2 (cg-RX-API-DMAC7.html)
EP (1) EP2321324A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011529942A (cg-RX-API-DMAC7.html)
KR (1) KR20110052686A (cg-RX-API-DMAC7.html)
CN (1) CN102171219A (cg-RX-API-DMAC7.html)
AU (1) AU2009279135B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917224A2 (cg-RX-API-DMAC7.html)
CA (1) CA2733235A1 (cg-RX-API-DMAC7.html)
EA (1) EA201170300A1 (cg-RX-API-DMAC7.html)
GB (1) GB0814340D0 (cg-RX-API-DMAC7.html)
IL (1) IL210777A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011001414A (cg-RX-API-DMAC7.html)
WO (1) WO2010015626A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100426B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01292A (cg-RX-API-DMAC7.html) * 2009-08-27 2015-06-05 Glaxosmithkline Llc
SI3297631T1 (sl) * 2015-05-18 2019-12-31 Nerre Therapeutics Limited Antagonist NK-1/NK-3 receptorja za zdravljenje oblivov vročine
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
MX2022005867A (es) 2019-11-15 2022-06-14 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274604B1 (en) 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
HRP20070471T3 (hr) * 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7683056B2 (en) * 2005-09-09 2010-03-23 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders

Similar Documents

Publication Publication Date Title
JP2011518833A5 (cg-RX-API-DMAC7.html)
JP2009149903A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2011529942A5 (cg-RX-API-DMAC7.html)
JP2012092103A5 (cg-RX-API-DMAC7.html)
JP2020502092A5 (cg-RX-API-DMAC7.html)
JP2017514910A5 (cg-RX-API-DMAC7.html)
JP2016514159A5 (cg-RX-API-DMAC7.html)
JP2010516681A5 (cg-RX-API-DMAC7.html)
JP2011529054A5 (cg-RX-API-DMAC7.html)
JP2014526533A5 (cg-RX-API-DMAC7.html)
MX2013003507A (es) Proceso de elaboracion para derivados de pirimidina.
JP2015508092A5 (cg-RX-API-DMAC7.html)
JP2012512863A5 (cg-RX-API-DMAC7.html)
JP2010521516A5 (cg-RX-API-DMAC7.html)
SMT201700142T1 (it) SALE DI CAMSILATO DI (1r, 1’R, 4R)-4-METOSSI-5’’-METIL-6’-[5-(PROP-1-IN-1-IL)PIRIDIN-3-IL]-3’H-DISPIRO[CICLOESANO-1,2’-INDEN-1’2’-IMIDAZOLO]-4’’-AMMINA E SUE FORME CRISTALLINE PER IL TRATTAMENTO DI PATOLOGIE A[BETA]-CORRELATE COME PER ESEMPIO LA MALATTIA DI ALZHEIMER
JP2016510768A5 (cg-RX-API-DMAC7.html)
JP2010534246A5 (cg-RX-API-DMAC7.html)
JP2009221198A5 (cg-RX-API-DMAC7.html)
JP2013513607A5 (cg-RX-API-DMAC7.html)
JP2011515406A5 (cg-RX-API-DMAC7.html)
JP2012511558A5 (cg-RX-API-DMAC7.html)
JP2011524898A5 (cg-RX-API-DMAC7.html)
JP2013541589A5 (cg-RX-API-DMAC7.html)